Infliximab (IFX), adalimumab (ADA), both monoclonal IgG antibodies, and etanercept (ETN), a fusion protein, are the mainstay of the anti-TNFα biologics used in RA patients in the United States [3]. The gene discussed is TNF; the disease is rheumatoid arthritis.